+

WO2002038577A3 - Derives d'erythromycine a liberation prolongee - Google Patents

Derives d'erythromycine a liberation prolongee Download PDF

Info

Publication number
WO2002038577A3
WO2002038577A3 PCT/US2001/032055 US0132055W WO0238577A3 WO 2002038577 A3 WO2002038577 A3 WO 2002038577A3 US 0132055 W US0132055 W US 0132055W WO 0238577 A3 WO0238577 A3 WO 0238577A3
Authority
WO
WIPO (PCT)
Prior art keywords
extended release
long chain
erythromycin derivatives
erythromycin derivative
release erythromycin
Prior art date
Application number
PCT/US2001/032055
Other languages
English (en)
Other versions
WO2002038577A2 (fr
Inventor
Sandra E Wassink
Donald J Treacy Jr
Edward M Rudnic
Original Assignee
Advancis Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advancis Pharmaceuticals filed Critical Advancis Pharmaceuticals
Priority to JP2002541109A priority Critical patent/JP2004528272A/ja
Priority to AU2002239232A priority patent/AU2002239232A1/en
Priority to EP01986972A priority patent/EP1333807A4/fr
Priority to CA002425688A priority patent/CA2425688A1/fr
Publication of WO2002038577A2 publication Critical patent/WO2002038577A2/fr
Publication of WO2002038577A3 publication Critical patent/WO2002038577A3/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La présente invention concerne une composition pharmaceutique constituée d'un dérivé d'érythromycine et d'un matériau non polymère assurant la libération prolongée, plus particulièrement un élément sélectionné dans le groupe formé par les argiles, les hydrocarbures à longue chaîne, les acides carboxyliques à longue chaîne, les esters d'acide carboxylique à longue chaîne, les alcools à longue chaîne et les mélanges de ces derniers; ledit élément étant présent suivant une quantité suffisante pour assurer la libération prolongée du dérivé d'érythromycine.
PCT/US2001/032055 2000-10-13 2001-10-12 Derives d'erythromycine a liberation prolongee WO2002038577A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002541109A JP2004528272A (ja) 2000-10-13 2001-10-12 持続型放出エリスロマイシン誘導体
AU2002239232A AU2002239232A1 (en) 2000-10-13 2001-10-12 Extended release erythromycin derivatives
EP01986972A EP1333807A4 (fr) 2000-10-13 2001-10-12 Derives d'erythromycine a liberation prolongee
CA002425688A CA2425688A1 (fr) 2000-10-13 2001-10-12 Derives d'erythromycine a liberation prolongee

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68998800A 2000-10-13 2000-10-13
US06/689,988 2000-10-13

Publications (2)

Publication Number Publication Date
WO2002038577A2 WO2002038577A2 (fr) 2002-05-16
WO2002038577A3 true WO2002038577A3 (fr) 2002-09-19

Family

ID=24770642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/032055 WO2002038577A2 (fr) 2000-10-13 2001-10-12 Derives d'erythromycine a liberation prolongee

Country Status (6)

Country Link
EP (1) EP1333807A4 (fr)
JP (1) JP2004528272A (fr)
AU (1) AU2002239232A1 (fr)
CA (1) CA2425688A1 (fr)
MX (1) MXPA03003146A (fr)
WO (1) WO2002038577A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122204B2 (en) 2000-02-24 2006-10-17 Advancis Pharmaceutical Corporation Antibiotic composition with inhibitor
US7282221B2 (en) 2000-10-13 2007-10-16 Middlebrook Pharmaceuticals, Inc. Antiviral product, use and formulation thereof
US8889187B2 (en) 2000-02-24 2014-11-18 Shionogi Inc. Once a day amoxicillin product comprising immediate and delayed release dosage forms
US9144548B2 (en) 2003-08-12 2015-09-29 Shionogi Inc. Antibiotic product, use and formulation thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
RU2440112C2 (ru) 2004-11-04 2012-01-20 Ксенопорт, Инк. Пероральная дозированная форма габапентина замедленного высвобождения

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3108046A (en) * 1960-11-25 1963-10-22 Smith Kline French Lab Method of preparing high dosage sustained release tablet and product of this method
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS49107855A (fr) * 1973-02-03 1974-10-14
JP2528652B2 (ja) * 1987-03-30 1996-08-28 エスエス製薬株式会社 持効性セフラジン製剤
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
CA2085342A1 (fr) * 1990-06-14 1991-12-15 Milton R. Kaplan Suspension aqueuse stable de medicament
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
JPH07267850A (ja) * 1994-03-28 1995-10-17 Eisai Co Ltd 不快味を防止した医薬組成物及びその製造方法
KR100404293B1 (ko) * 1995-05-02 2004-02-18 다이쇼 세이야꾸 가부시끼가이샤 경구투여용조성물
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5780604A (en) * 1997-09-26 1998-07-14 Abbott Laboratories 11,12-cyclic phosphite or phosphate derivatives of erythromycin and related macrolides
JP2000169364A (ja) * 1998-09-30 2000-06-20 Taisho Pharmaceut Co Ltd 経口製剤用粒子
EP1161956A4 (fr) * 1999-03-17 2005-03-16 Daiichi Seiyaku Co Compositions medicamenteuses
SI20244A (sl) * 1999-05-19 2000-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Granulacija v talini

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3108046A (en) * 1960-11-25 1963-10-22 Smith Kline French Lab Method of preparing high dosage sustained release tablet and product of this method
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1333807A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122204B2 (en) 2000-02-24 2006-10-17 Advancis Pharmaceutical Corporation Antibiotic composition with inhibitor
US8889187B2 (en) 2000-02-24 2014-11-18 Shionogi Inc. Once a day amoxicillin product comprising immediate and delayed release dosage forms
US7282221B2 (en) 2000-10-13 2007-10-16 Middlebrook Pharmaceuticals, Inc. Antiviral product, use and formulation thereof
US9144548B2 (en) 2003-08-12 2015-09-29 Shionogi Inc. Antibiotic product, use and formulation thereof

Also Published As

Publication number Publication date
AU2002239232A1 (en) 2002-05-21
CA2425688A1 (fr) 2002-05-16
JP2004528272A (ja) 2004-09-16
MXPA03003146A (es) 2004-12-06
EP1333807A2 (fr) 2003-08-13
WO2002038577A2 (fr) 2002-05-16
EP1333807A4 (fr) 2005-06-29

Similar Documents

Publication Publication Date Title
DE60006070D1 (de) Pyrazolcarbonsäurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
AU2001271027A1 (en) Ester derivatives
AU2002230689A1 (en) Methods for detection of a nucleic acid by sequential amplification
AU2001284324A1 (en) Controlled release formulation of erythromycin or a derivative thereof
AU3906701A (en) Permeable composition, controlled release product and methods for the productionthereof
AU2001290075A1 (en) Novel alkanoic acid derivatives
CA2313878A1 (fr) Composition permettant d'eliminer les problemes de comportement chez les animaux de compagnie
AUPR183100A0 (en) Wood products and processes for the preparation thereof
AU2001231730A1 (en) Piperidyl carboxylic acids as integrin antagonists
WO2002038577A3 (fr) Derives d'erythromycine a liberation prolongee
AU2001271085A1 (en) Organic acid producing microorganism and process for preparing organic acids employing the same
ID29110A (id) Komposisi dan proses untuk pemindahan gas-gas asam
AU2001232238A1 (en) Anti-acid-fast bacterial agents containing pyridonecarboxylic acids as the active ingredient
MXPA03002901A (es) Derivados de acido propionico.
ATE294175T1 (de) 4-sulfonamid-piperidin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
AU2001234107A1 (en) Benzoic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
AU2002214978A1 (en) Beta-Thio-amino acids
HUP0302912A3 (en) Betha-thio-amino acids, process for their preparation and pharmaceutical compositions containing them
AU2001296089A1 (en) Propionic acid based preservative agent for animal and vegetable products
AU2001271015A1 (en) Article formed into honeycomb
DE602004005734D1 (de) Pharmazeutische zusammensetzung mit kontrollierter freisetzung und verfahren zu ihrer herstellung
ATE244246T1 (de) Pyridothienodiazepine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
AU2001255528A1 (en) A member and a method for using the member to selectively create an item
AU2001227139A1 (en) Injection molding composition comprising paper and method for preparing the same
ATE275140T1 (de) Zns wirksame cyclobuta-indole-carboxamide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische präparate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2425688

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002541109

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002239232

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001986972

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001986972

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001986972

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载